Physician
Oncology
Dr. Paul R. Conkling, MD
|
|
Give Review
Paul Conkling works in the field of Oncology. He went to The Ohio State University College of Medicine. He has 4 awards "Regional Top Doctor", "Meaningful Use Stage 1 Certification", "Top MD" and "Super Doctor". Doctor Paul R. Conkling, MD is a published MD. He published 24 publications, including: 'Comparison of antibody-dependent cytotoxicity mediated by human polymorphonuclear cells, monocytes, and alveolar macrophages.' He accepts all Medicare patients.
Publications
- A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
- An innovative, multi-arm, complete phase 1b study of the novel anti-Cancer agent tasisulam in patients with advanced solid tumors.
- A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic Cancer.
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer.
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cel...
- Thrombosis in Acute promyelocytic leukemia.
- Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer.
- Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast Cancer.
- Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung Cancer sensitive to first-line platinum-base...
- A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic Cancer.
- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung Cancer.
- Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung Cancer patients age
- Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung Cancer with Eastern Cooperative Oncology Group Performance...
- Sphingosine inhibits monocyte tissue factor-initiated Coagulation by altering factor VII binding.
- Human mononuclear phagocyte transglutaminase activity cross-links fibrin.
- Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.
- Tumor necrosis factor induces tissue factor-like activity in human Leukemia cell line U937 and peripheral blood monocytes.
- Identification of normal human peripheral blood monocytes and liver as sites of synthesis of Coagulation factor XIII a-chain.
- Brown blood: understanding methemoglobinemia.
- Effect of diethyldithiocarbamate (DDC) on human monocyte function and metabolism.
- Comparison of antibody-dependent cytotoxicity mediated by human polymorphonuclear cells, monocytes, and alveolar macrophages.
- Oxygen dependence of human alveolar macrophage-mediated antibody-dependent cytotoxicity.
- Activation of monocyte and granulocyte antibody-dependent cytotoxicity by phorbol myriState acetate.
Schools
Ohio State University College Of Medicine and Public Health
Duke University Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
- Top MD
- Super Doctor
Education
-
Duke University Hospital -
The Ohio State University College of Medicine
Hospital
-
Duke University Hospital
Drug Facts
| NPI NUMBER | 1063417806 | |
| NPPES Provider LastName | CONKLING | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 235021871 | |
| NPPES Provider State | VA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 601.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 117.0 | |
| Percent Opioid Claims | 19.47 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063417806 |
| Last Name Of The Provider | CONKLING |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Thomas A. Alberico, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael E. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Danso, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ranjit K. Goudar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michele R. Roullet, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott J. Cross, MD |
|
|
Dr. Gauri V. Radkar, DO
This Doctor is OpenDoctor Recommended.
|